TRENDYVEST.COM | BIOTECH | WEEK IN REVIEW

By Nicholas Thomas | June 26, 2026

It was the kind of week that gets written about in industry textbooks. Three blockbuster acquisitions. A cancer drug that had been rejected twice by the FDA getting a third chance at approval. Eli Lilly surging on a leukemia breakthrough in Europe. A psychedelics company raising $805 million. And venture capitalists writing nine-figure checks so fast that BioPharma Dive called it one of the busiest fundraising weeks since April.

While the rest of Wall Street was hand-wringing over chip stocks and OpenAI's IPO drama, the life sciences sector quietly put together one of the most consequential weeks of 2026. The money moved. The deals closed. And the signals — if you know how to read them — point toward a fundamental realignment of where the next decade of medicine is being built.

Here is every story that mattered, and what it actually means.

THE OPENING SHOT: ABBVIE BETS $10.9 BILLION ON A DUPIXENT KILLER

Monday morning, AbbVie pulled the trigger on a deal the industry had been speculating about for months. AbbVie agreed to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the transaction at approximately $10.9 billion. The boards of both companies unanimously approved the deal, which is expected to close in the third quarter of 2026.

The asset at the center of it is zumilokibart — an experimental monoclonal antibody targeting IL-13, a key driver of inflammation in atopic dermatitis and asthma. Shares of Apogee surged 47% in premarket trading. The acquisition is AbbVie's largest in more than five years.

To understand why AbbVie paid this price, you need to understand what they are racing against. Their blockbuster immunology drugs Skyrizi and Rinvoq — which together generate tens of billions in annual revenue — are approaching patent cliffs. The company needs next-generation assets that can sustain its immunology franchise through the 2030s. Zumilokibart is designed to do exactly that.

But here is the detail that makes this deal genuinely interesting. Sanofi and Regeneron's Dupixent is currently the world's best-selling drug in atopic dermatitis, with over $10 billion in annual sales. It requires an injection every two weeks. Zumilokibart is being studied as a subcutaneous injection given once every three or six months — a substantial reduction in dosing frequency that could be transformative for patient convenience and market penetration.

If zumilokibart delivers that dosing advantage in late-stage trials, AbbVie won't just have a competitor to Dupixent. It will have a potential successor. That is worth ten point nine billion dollars.

THURSDAY: MERCK KGAA DROPS $11.3 BILLION ON THE TOOLS THAT BUILD DRUGS

Twenty-four hours after AbbVie's announcement, Thursday brought a deal of a different kind — and in many ways, a more revealing one.

German drugmaker Merck KGaA announced it will acquire U.S. biotech firm Bio-Techne for $11.3 billion — its largest deal in over a decade. Merck will pay $73 per share in cash, a 36% premium to Bio-Techne's one-month average trading price. Shares of Bio-Techne surged 22% in premarket trading.

Bio-Techne is not a drug company. It does not sell medicines to patients. What it sells are the instruments, proteins, antibodies, reagents, and analytical tools that pharmaceutical and biotech companies use to develop drugs. It is, in the language of the sector, a picks-and-shovels play — the company that sells the equipment to the gold miners rather than mining for gold itself.

Bio-Techne increased its sales from $714 million in 2019 to $1.2 billion in 2025. The advanced therapy manufacturing sector — which includes the cell therapy tools that represent Bio-Techne's fastest-growing business — is expanding at over 20% annually.

Merck is making a deliberate strategic bet. Rather than acquiring a single drug candidate with binary clinical risk, it is buying infrastructure — a position embedded across hundreds of pharmaceutical customers from early discovery through commercial manufacturing. When the cell and gene therapy wave matures into commercial-scale production, every single batch of those therapies will require the kind of materials and quality-control tools that Bio-Techne supplies.

The deal is Merck's largest since it spent $17 billion acquiring Sigma-Aldrich in 2015 — also a life sciences tool manufacturer. The parallel is not accidental. Sigma-Aldrich turned out to be one of the most durable acquisitions in German pharma history. Merck is betting Bio-Techne will be the same.

Completing the week's M&A trifecta: GSK bought cancer specialist Nuvalent for $10.6 billion in June, adding targeted therapies for ROS1 and ALK mutations in non-small cell lung cancer — among the most genetically defined and commercially validated cancer subsets in oncology.

Three deals. Thirty-three billion dollars. Five days.

ELI LILLY SURGES 6% ON A LEUKEMIA WIN THAT MOST PEOPLE MISREAD

Friday morning, before the market opened, Eli Lilly delivered the week's clearest individual catalyst. Lilly shares climbed nearly 6% after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Jaypirca — known generically as pirtobrutinib — for adults with chronic lymphocytic leukemia across all lines of therapy, regardless of prior treatment with BTK inhibitors. The European Commission's final decision is expected within one to two months.

Most coverage treated this as a straightforward regulatory win. It is considerably more than that.

CLL is the most common form of leukemia in adults, and the treatment landscape has been dominated for years by covalent BTK inhibitors — drugs like ibrutinib and acalabrutinib. Those drugs work extraordinarily well, until they stop working. When patients develop resistance and progress on those agents, the options narrow dramatically.

Jaypirca is a non-covalent BTK inhibitor, which means it binds to the BTK enzyme in a fundamentally different way — one that allows it to work even in patients who have developed resistance to the older generation of drugs. The CHMP's recommendation covers patients at every stage of CLL and every line of therapy, which means Jaypirca can now be used from a patient's first treatment all the way through to the final line. That is the full commercial spectrum of the disease in Europe.

Lilly has also submitted the same data to the FDA, with a U.S. regulatory decision expected in the second half of 2026. A U.S. approval of this scope would make Jaypirca one of the most versatile CLL therapies on the market — and a major growth driver for a company that is already on one of the most impressive runs in pharmaceutical history.

THE COMEBACK STORY: A MELANOMA DRUG GETS ITS THIRD SHOT AT THE FDA

Of everything that happened this week in biotech, this is the story with the most human weight behind it.

Replimune's RP1 — known clinically as vusolimogene oderparepvec — is an oncolytic virus therapy for advanced melanoma. It uses a genetically modified version of the herpes simplex virus to infect and destroy tumor cells while simultaneously triggering the patient's immune system to attack the cancer more broadly. In combination with Bristol Myers Squibb's nivolumab, it showed remarkable results in a patient population with almost nowhere left to turn.

The FDA rejected it. Then rejected it again. Both times under leadership that critics across the oncology community accused of providing inconsistent feedback and moving regulatory goalposts. The new FDA leadership took a different view.

On Friday, the FDA accepted Replimune's resubmission of the BLA for RP1 plus nivolumab for advanced melanoma as a complete, class 1 response, with a goal date of August 2, 2026, and an advisory committee meeting scheduled for late July.

The data that supports this application is striking. The IGNYTE trial showed an overall response rate of approximately 33% in patients who had already progressed on anti-PD-1 therapy, a median duration of response of 33.7 months, and a three-year overall survival rate of 83.5% among responders.

Read that last number again. Nearly 84% of patients who responded to RP1 plus nivolumab were still alive three years later — in a population that had already failed the standard of care. For context, advanced melanoma patients who progress on immunotherapy historically have a median survival measured in months, not years.

The August 2 decision date is now one of the most important dates on the oncology calendar this summer. If approved, RP1 would represent not just a win for Replimune but a vindication of the oncolytic virus approach to cancer treatment — and a signal that the new FDA is willing to correct its own institutional mistakes when the evidence demands it.

THE VENTURE CAPITAL WAVE: $450 MILLION IN ONE WEEK, AND THE DEALS KEEP COMING

While the big acquisitions grabbed the headlines, the private markets were moving just as aggressively.

Five privately held biotech companies announced a combined $450 million in venture funding this week — one of the busiest fundraising weeks since April.

The standout was Ollin Biosciences. The Texas-based ophthalmology company closed a $330 million Series B round backed by ARCH Venture Partners, Andreessen Horowitz's bio+health fund, Blackstone Multi-Asset Investing, the Canada Pension Plan Investment Board, RA Capital Management, and T. Rowe Price. Ollin is developing OLN324, a bispecific antibody targeting VEGF and Ang2 for eye diseases including wet AMD and diabetic macular edema — conditions that affect tens of millions of people globally.

What makes the Ollin raise particularly notable is the strategic context. Roche's Vabysmo — itself a VEGF/Ang2 bispecific — is currently one of the top-selling ophthalmology drugs in the world. Ollin's early data suggested OLN324 has certain advantages over Vabysmo in head-to-head comparison. The company is now preparing for at least three simultaneous Phase 3 trials — an extraordinarily aggressive clinical strategy that the Series B will fund. That investor syndicate, which includes some of the most sophisticated life sciences capital in the world, does not commit $330 million to a company preparing for three Phase 3 programs without high conviction in the data.

Elsewhere, Definium Therapeutics announced an $805 million stock issuance to fund its psychedelics pipeline. Its lead compound DT120 — an oral disintegrating tablet being developed for major depression — just hit its Phase 3 primary endpoint. Five years ago, a psychedelics company raising eight hundred million dollars would have been unthinkable to mainstream pharma. Today it barely registered as a surprise. The field has arrived.

Vedana Therapeutics emerged from stealth with $46 million to develop anti-PACAP therapies for migraine prevention — one of the most scientifically compelling mechanisms in headache medicine that has yet to be fully commercially validated. And across the sector, the FDA approved 24 drugs in May 2026 alone — bringing the year-to-date total to 84 approvals, a pace that if sustained would make 2026 one of the most productive regulatory years in modern pharmaceutical history.

THE FDA IS CHANGING. THE INDUSTRY CAN FEEL IT.

The through-line connecting Replimune's third BLA acceptance, the agency's positive momentum across multiple regulatory decisions this week, and the broader tone shift at the FDA is impossible to ignore. The agency took another step toward clearing a backlog of what BioPharma Dive described as Makary-era rejections that appeared to contradict earlier agreements with drugmakers.

For an industry that spent the better part of two years operating in regulatory uncertainty — never entirely sure what standard of evidence would be required, or whether goalposts would move mid-review — the change in tone matters enormously. Drug companies make ten-year investment decisions based on their confidence in the regulatory environment. When that environment stabilizes and becomes more predictable, capital flows back in. Clinical programs that were paused get restarted. Drugs that were mothballed after rejection get reconsidered.

That is what you are watching unfold across biotech right now. It is not a coincidence that M&A is surging at the same moment the FDA is becoming more legible. Acquirers can underwrite risk more confidently when they know what the rules are.

THE MACRO PICTURE: WHY THIS WEEK WAS NOT AN ACCIDENT

Zoom out from the individual deals and a structural story emerges. U.S. pharma and life sciences deal value in the first quarter of 2026 surpassed $65 billion — the strongest quarter since pandemic-related highs in 2020. The pace has not slowed. If anything, this week suggests it is accelerating.

The driving force is patent expiration math that the industry cannot escape. The drugs that generated blockbuster revenue for big pharma over the past decade are losing exclusivity on a rolling basis through the late 2020s and early 2030s. Organic drug discovery — even turbocharged by artificial intelligence — cannot replenish those revenues fast enough. So the industry is buying. And the prices they are paying reflect a genuine scarcity of late-stage, differentiated assets with clear commercial paths.

For investors, that scarcity creates a specific dynamic. The companies sitting on Phase 2 and Phase 3 assets in validated therapeutic areas — immunology, oncology, neurology — are not just clinical-stage biotechs. They are acquisition targets in a seller's market. The M&A wave is not over. Based on the patent cliff math, it is barely half finished.

This was a week that told you exactly where the next decade of medicine is being built — who is paying for it, who is betting on it, and which science is close enough to the finish line that the world's largest pharmaceutical companies are writing ten-billion-dollar checks to own it.

That is the real biotech story of June 26, 2026. And almost nobody was paying attention.

— Nicholas Thomas | TrendyVest.com | June 26, 2026